Table 2.
Time to SRE | Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | ||
Gender | Female Male |
0.713 | 0.451–1.125 | 0.146 | |||
Age at diagnosis | ≥50 <50 |
0.801 | 0.399–1.608 | 0.533 | |||
Smoking status | Yes No/Unknown |
1.425 | 0.893–2.273 | 0.137 | |||
Performance status (ECOG) | ≥2 0–1 |
2.103 | 1.037–4.263 | 0.039 | 2.124 | 1.046–4.313 | 0.037 |
EGFR mutation ex 19 | Yes No |
0.974 | 0.601–1.580 | 0.916 | |||
Number of metastatic sites | Only BM 2 ≥3 |
0.517 0.744 |
0.127–2.112 0.357–1.551 |
0.499 0.358 0.430 |
|||
Synchronous mets | Yes No |
0.963 | 0.572–1.622 | 0.888 | |||
Visceral mets | Yes No |
1.233 | 0.718–2.118 | 0.448 | |||
Lung mets | Yes No |
0.931 | 0.737–1.177 | 0.550 | |||
Liver mets | Yes No |
1.741 | 1.070–2.833 | 0.026 | 1.946 | 1.169–3.239 | 0.010 |
Lymph nodes | Yes No |
1.030 | 0.612–1.733 | 0.912 | |||
SNC mets | Yes No |
1.308 | 0.829–2.064 | 0.248 | |||
Adrenal mets | Yes No |
0.676 | 0.325–1.407 | 0.295 | |||
Number of bone mets sites | 1–2 3–4 5–10 |
0.671 0.691 |
0.382–1.178 0.374–1.275 |
0.337 0.165 0.237 |
|||
Hemoglobin | ≤12 g/dl (women); ≤14 (men) Normal value |
0.976 | 0.521–1.830 | 0.939 | |||
ALP | ≥220 U/I Normal value |
1.725 | 0.798–3.729 | 0.166 | |||
LDH | ≥300 U/I Normal value |
0.921 | 0.450–1.885 | 0.821 |
Univariate and multivariate analyses of risk factors associated with SRE occurrence according to Cox’s proportional hazards regression model (SRE, skeletal related event).
Bold values denote statistical significance at the p < 0.005 level.